Matrix metalloproteinases (MMPs, aka matrixins) are zinc-dependent endopeptidases that are members of the metzincin-superfamily of enzymes. The first MMP (MMP-1) was discovered in tadpoles during embryogenesis (1), hinting at the prominent role that MMPs play in growth and development. Indeed, MMPs are a collection of enzymes that are chiefly responsible for the physiological turnover of extracellular matrix (ECM) and connective tissues in embryogenesis, organogenesis, angiogenesis, and tissue repair/remodeling. While typically found in low amounts in healthy adult tissues, MMP activity can be upregulated in pathologies where turnover of connective tissues and ECM are a defining feature, such as: arthritis (2), chronic allergic asthma (3), cancer (4), nephritis (5), and fibrotic diseases (6).
All MMPs share two domains: a propeptide domain and an N-terminal catalytic domain containing a Zn2+ ion critical for MMP proteinase activity. Most MMPs also possess a C-terminal hemopexin-like domain that is vital for binding to collagen fibers, although MMP-7, MMP-23, and MMP-26 lack this domain. MMPs released into the extracellular space are typically zymogens, latent enzymes that need to be activated by other enzyme activity. A cysteine residue in the propeptide domain blocks the active site by interacting with the Zn2+ at the active site, rendering the enzyme inactive. Chemical modification or proteolytic removal of the pro-peptide domain by other proteinases, including other MMPs, will activate the MMP molecule. This activation mechanism, called a cysteine switch, is common to almost all MMP molecules identified thus far (7).
Figure 1. Typical tertiary structure of soluble MMP showing the A) Inactive pro-MMP (zymogen), containing the pro-domain, B) Active MMP (with the pro-domain enzymatically removed and the Zn2+ ion in the active site exposed), and C) andTIMP complexed with MMP (inactive).
Image from: T. T. Nguyen, S. Mobashery, M. Chang, Roles of Matrix Metalloproteinases in Cutaneous Wound Healing, Wound Healing - New insights into Ancient Challenges, IntechOpen, DOI: 10.5772/64611
Traditionally, MMPs have been categorized based on their substrate specificities and their form. Membrane-type MMPs (MT-MMP) are incorporated into cell membranes by a transmembrane domain or tethered to cell membranes by a glycosylphosphatidylinositol (GPI)-anchor. Soluble MMPs (collagenases, gelatinases, stromelysins, matrilysins, macrophage elastase) can be found free in the ECM or in cell vesicles where they are stored until stimulated for release. These soluble MMP classifications are based on shared substrate specificities and similarities in their structures:
However, MMPs appear to exhibit a much broader proteolytic activity (at least in vitro) than originally thought. Many MMPs have proteolytic activity against numerous ECM proteins, as well as non-ECM components, such as growth factor-binding proteins (8), cell surface growth factor receptors (8), as well as cytokines and chemokines (9). This ability to modulate inflammatory signaling and chemotactic signaling molecules intimates a wider regulatory role for MMPs than initially thought. However, proteolytic processing of cytokines and chemokines by MMP is a complicated pathway. Indeed, cleavage of cytokines and chemokines by various MMPS can lead to activation or inactivation of the signaling molecule, with either agonist or antagonist effector functions (9). More research is needed to determine the how MMP cleavage of cytokines and chemokines affects immune responses and disease progression.
The table below provides more information on the reported substrates of most MMPs, as well as the physiological functions associated with MMP activity.
|
Also Known As |
Category |
Substrates |
Physiological Functions |
---|---|---|---|---|
MMP-1 |
Collagenase 1 |
Collagenase |
Aggrecan, Versican, Perlecan, Nidogen, Serpins, Tenascin C, Native Collagen, CXCL12, CCL7, CCL2, CCL13 |
Embryogenesis |
MMP-2 |
Gelatinase A |
Gelatinase |
Gelatin, Collagen (I, IV, V), Elastin, Vitronectin, IL-1β, TGF-β, CXCL12, CX3CL1, CCL7 |
Neovascularization/ |
MMP-3 |
Stromelysin 1 |
Stromelysins |
Fibronectin, Gelatin, Laminin, Proteoglycans, Globular Type IV, IL-1β, TGF-β, CXCL12, CCL2, CCL7, CCL8, CCL13 |
MMP activation; Wound healing; Involution |
MMP-7 |
Matrilysin 1 |
Matrilysin |
Fibronectin, Gelatin, Laminin, Elastin, proMMP-2, proMMP-9 |
Endometrial involution; |
MMP-8 |
Collagenase 2 |
Collagenase |
Collagen (I, II, III, V, VII, VIII, X), Gelatin, Aggrecan, Fibronectin, CXCL5, CXCL8, CXCL9, CCL2, CXCL5 |
Embryogenesis; Uterine tissue |
MMP-9 |
Gelatinase B |
Gelatinase |
Collagen (IV), IL-8, IL-1β, TGF-β, IFN-β CXCL12, CXCL4, CXCL1, CTAPIII, CXCL5, CXCL8, CXCL9 |
Neovascularization; Immune |
MMP-10 |
Stromelysin 2 |
Stromelysins |
Collagen (III, IV, V), Gelatin, Aggrecan |
Bone Remodeling, Ossification; |
MMP-11 |
Stromelysin 3 |
Stromelysins |
Casein, Fibronectin, Vitronectin, Laminin, Entactin, Proteoglycans, Fibrinogen, Fibrin, Plasminogen |
-- |
MMP-12 |
Macrophage Elastase |
Elastase |
Elastin, Plasminogen |
-- |
MMP-13 |
Collagenase 3 |
Collagenase |
Collagen (I, II, III, IV, IX, XIV), Gelatin, Aggrecan, Perlecan, Fibronectin, Tenascin-C, CXCL12, CCL7 |
Bone Development; |
MMP-14 |
MT1-MMP |
Membrane-Type |
Collagen (I, II, III), Fibronectin, Vitronectin, Tenascin, Nidogen, Aggrecan, Fibrin, Fibrinogen, Laminin-5, proMMP-2, proMMP-13, proMMP-8, TGF-β, CXCL12, CCL7 |
Angiogenesis; Endothelial cell |
MMP-15 |
MT2-MMP |
Membrane-Type |
Collagen (I, II, III), Fibronectin, Vitronectin, Tenascin, Nidogen, Aggrecan, Fibrin, Fibrinogen, Laminin-5, proMMP-2, proMMP-13, proMMP-9 |
Ovulation (follicle rupture) |
MMP-16 |
MT3-MMP |
Membrane-Type |
proMMP-2 |
-- |
MMP-17 |
MT4-MMP |
Membrane-Type |
Gelatin, Fibrin, Fibrinogen |
-- |
MMP-20 |
Enamelysin |
N/A |
Amelogenin |
Tooth enamel turnover |
MMP-25 |
MT6-MMP |
Membrane-Type |
Gelatin, Fibrin, Fibrinogen, Fibronectin, Collagen (IV), Proteoglycans, proMMP-2 |
-- |
MMP-26 |
Matrilysin 2 |
N/A |
Fibronectin, proMMP-2, proMMP-9 |
-- |
Table 1. Common MMPs, their alternative names, classifications, known substrates, and studied physiological functions.
Table compiled based on information provided by:
1. T. Klein, R. Bischoff, Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 41, (2):271-290 (2011). doi:10.1007/s00726-010-0689-x.
2. P. Van Lint, and C. Libert, Chemokine and cytokine processing by matrix metalloproteinases and its effect on leukocyte migration and inflammation. Journal of Leukocyte Biology 82, 1375-1381 (2007).
The ability of MMPs to influence immune cell behavior and inflammatory reactions makes regulation of MMP activity key for maintaining homeostasis. Transcription (expression) level regulation and the cysteine switch activation method described above are the primary regulatory mechanisms. However, endogenous Tissue Inhibitors of MetalloProteinases (TIMPs), a group of four broad-spectrum inhibitors (TIMP-1, TIMP-2, TIMP-3, TIMP-4) with varying affinities for different metalloproteinases, also play important roles in managing MMP activity (10). Dysregulation of MMP activity can be a driving force in diseases where collagen degradation and tissue remodeling are prominent features (osteaoarthritis, rheumatoid arthritis, cancer, asthma). Compounds that can specifically inhibit MMPs associated with disease pathologies could be key therapeutic targets for improving treatment options.
References